Authors

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Rachid Baz, MD

Latest:

Dr Baz on AE Management Discussions in Multiple Myeloma

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Rachna T. Shroff, MD, MS

Latest:

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Rachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma.

Radhakrishnan Ramchandren MD

Latest:

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

Radhakrishnan Ramchandren, MD, Wayne State University School of Medicine

Radhika Prabhaker, MD

Latest:

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Radka Stoyanova, PhD

Latest:

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Rafael Bejar, MD, PhD, UCSD

Rafael Bejar MD, PhD, UCSD Moores Cancer Center

Rafael Fonseca, MD

Latest:

Dr Fonseca on Selecting a Treatment in Relapsed/Refractory Myeloma

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, Mayo Clinic

Rafael Fonseca, MD, The Mayo Clinic in Phoenix Arizona

Rafat Abonour, MD

Latest:

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Raffaele Califano, MD

Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK.

Latest:

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Raffit Hassan, MD

Latest:

Dr. Hassan on Immunotherapy in Malignant Pleural Mesothelioma

Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

Raghava R. Induru, MD

Latest:

Dr. Induru Discusses Other Mutations in Lung Cancer

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

Ragini Kudchadkar, MD

Latest:

Dr. Kudchadkar on Future Research Directions for Rare, Non-Melanoma Skin Cancers

Ragini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.

Ragini R. Kudchadkar, MD

Latest:

Dr. Kudchadkar on the Biological Differences Between Ocular and Cutaneous Melanoma

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Rahul Aggarwal, MD

Latest:

Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.

Rahul D. Tendulkar, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.